Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

The advent of immune-checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis, produced a paradigm change of the treatment algorithm for metastatic, non-oncogene addicted, non-small cell lung cancer (NSCLC). However, the majority of patients with on...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Lung Cancer Res
Hlavní autoři: Leone, Gianmarco, Passiglia, Francesco, Bironzo, Paolo, Bertaglia, Valentina, Novello, Silvia
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2020
Témata:
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7815346/
https://ncbi.nlm.nih.gov/pubmed/33489826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-710
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky